» Articles » PMID: 8369596

Diltiazem. A Review of Its Pharmacology and Therapeutic Use in Older Patients

Overview
Journal Drugs Aging
Specialties Geriatrics
Pharmacology
Date 1993 Jul 1
PMID 8369596
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Diltiazem is a benzothiazepine derivative calcium antagonist available in several formulations, some of which enable once daily administration. The drug as monotherapy has demonstrated similar efficacy to diuretics in older patients with hypertension. Data comparing diltiazem with beta-blockers and angiotensin converting enzyme inhibitors are more limited, but available studies suggest at least comparable antihypertensive efficacy. Diltiazem as monotherapy or in combination with a beta-adrenoceptor-antagonist, isosorbide dinitrate, or another calcium antagonist, has demonstrated efficacy in patients with effort angina. The drug has also been used intravenously to terminate supraventricular tachycardias and to control the ventricular response to atrial fibrillation or flutter; it also appears to reduce the rate of early reinfarction in patients with non-Q-wave myocardial infarction. The most common adverse events during diltiazem therapy include headache, flushing, peripheral oedema and hypotension. Atrioventricular block although rare, is the most frequent serious adverse event related to diltiazem therapy and may be exacerbated by coadministration of beta-adrenoceptor antagonists, especially in the elderly. Thus, diltiazem appears to be an effective and well tolerated treatment for hypertension and angina in older patients and has shown promise as therapy for supraventricular tachycardias and as prophylaxis against early reinfarction in patients with non-Q-wave myocardial infarction.

Citing Articles

[Not Available].

Debregeas B, Duchier J Clin Drug Investig. 1997; 13(2):59-65.

PMID: 18370452 DOI: 10.2165/00044011-199713020-00001.


Drug-induced orthostatic hypotension in the elderly: avoiding its onset.

Verhaeverbeke I, Mets T Drug Saf. 1997; 17(2):105-18.

PMID: 9285201 DOI: 10.2165/00002018-199717020-00003.

References
1.
Rovei V, Gomeni R, Mitchard M, LARRIBAUD J, BLATRIX C, Thebault J . Pharmacokinetics and metabolism of diltiazem in man. Acta Cardiol. 1980; 35(1):35-45. View

2.
Mogensen C . Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). 1982; 285(6343):685-8. PMC: 1499854. DOI: 10.1136/bmj.285.6343.685. View

3.
Strauss W, Parisi A . Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation. 1985; 71(5):951-7. DOI: 10.1161/01.cir.71.5.951. View

4.
Pichard L, Gillet G, Fabre I, Bonfils C, Thenot J, Maurel P . Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos. 1990; 18(5):711-9. View

5.
Busse J, Materson B . Geriatric hypertension: the growing use of calcium-channel blockers. Geriatrics. 1988; 43(2):51-4, 57-8. View